Carolina Wealth Advisors LLC Buys 375 Shares of Eli Lilly and Company $LLY

Key Points

• Carolina Wealth Advisors LLC increased its stake in Eli Lilly and Company by 40%, acquiring an additional 375 shares, bringing its total ownership to 1,312 shares worth approximately $1,023,000.
• Recent insider transactions include EVP Daniel Skovronsky and Director J Erik Fyrwald both purchasing shares, indicating growing confidence in the company's future; Skovronsky acquired 1,000 shares while Fyrwald bought 1,565 shares.
• Eli Lilly's latest earnings report revealed a strong quarter with earnings of $6.31 EPS, surpassing expectations, and a revenue of $15.56 billion, reflecting a 37.6% year-over-year increase.

Carolina Wealth Advisors LLC boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 40.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,312 shares of the company's stock after acquiring an additional 375 shares during the period. Carolina Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $1,023,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Family CFO Inc bought a new position in shares of Eli Lilly and Company during the 2nd quarter worth $54,000. Duquesne Family Office LLC lifted its holdings in Eli Lilly and Company by 52.5% during the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock valued at $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC bought a new position in Eli Lilly and Company during the first quarter worth about $570,000. Cutter Capital Management LP purchased a new position in shares of Eli Lilly and Company in the first quarter worth about $14,866,000. Finally, Emerald Advisors LLC raised its position in shares of Eli Lilly and Company by 60.8% in the second quarter. Emerald Advisors LLC now owns 1,021 shares of the company's stock valued at $796,000 after purchasing an additional 386 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Leerink Partners reaffirmed a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a research report on Monday, August 11th. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating on the stock in a research report on Friday. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $938.94.

Eli Lilly and Company Trading Up 2.5%

Shares of LLY opened at $840.46 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a market capitalization of $795.47 billion, a P/E ratio of 54.93, a P/E/G ratio of 1.17 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm's 50 day simple moving average is $734.60 and its 200 day simple moving average is $765.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.